Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration

A pyridylamine and compound technology, which is applied in the directions of drug combination, antitumor drug, pharmaceutical formulation, etc., to achieve the effect of low toxicity and remarkable therapeutic effect

Inactive Publication Date: 2013-08-28
GMAX BIOPHARM
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to solve the problem of how to effectively apply ALK inhibitors in treatment, and to provide an application of a pyridinamine compound in the preparation of a drug for the treatment of lung cancer suitable for oral administration, so that it can be effectively applied to EML4-ALK positive The treatment of non-small cell lung cancer, the treatment effect is remarkable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration
  • Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration
  • Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The pyridinamine compound of the structure shown in formula I is made into tablet (preparation method is conventional technology), for the treatment of EML4-ALK positive non-small cell lung cancer, the content of the pyridinamine compound of structure shown in formula I in the tablet is 340mg , Adults take 2 times a day, 1 tablet each time.

Embodiment 2

[0036] The pyridinamine compound of the structure shown in formula I is made into tablet (preparation method is conventional technology), for the treatment of EML4-ALK positive non-small cell lung cancer, the content of the pyridinamine compound of structure shown in formula I in the tablet is 640mg , Adults take 1 tablet per day, 1 tablet each time.

Embodiment 3

[0038] The mixture of the pyridinamine compound with the structure shown in formula I and the benzenesulfonate salt of the pyridinamine compound with the structure shown in formula I is made into tablets (the preparation method is conventional technology), which is used for non-small children with EML4-ALK positive For the treatment of cell lung cancer, the content of the pyridinamine compound of the structure shown in the formula I in the tablet (convert the benzenesulfonate of the pyridinamine compound of the structure shown in the formula I into the pyridinamine compound of the structure shown in the formula I) content is 100 mg, and the adult daily Take 2 times, 2 tablets each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a pyridylamine compound in preparation of a pharmaceutical composition used for treating a lung cancer and suitable for oral administration and aims to overcome problems in effective application of an ALK inhibitor in treatment. The pharmaceutical composition provided by the invention contains the pyridylamine compound having a structure as represented by formula I, an active component and an optional pharmaceutically acceptable carrier, adjuvant or excipient, wherein the active component is one or a mixture of two selected from the group consisting of pharmaceutically acceptable salts of the pyridylamine compound, and the effective treatment dose of the pharmaceutical composition is 340 to 680 mg / d in terms of the amount of the pyridylamine compound having the structure as represented by formula I. The pyridylamine compound can be effectively applied in treatment of EML4-ALK-positive non-small cell lung cancers and has a substantial treatment effect and low toxic response.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a pyridinamine compound in the preparation of a drug for treating lung cancer suitable for oral administration. Background technique [0002] The incidence of lung cancer ranks first among tumors. There are 1.2 million new lung cancer patients worldwide each year (85% are non-small cell lung cancers). EML4-ALK-positive non-small cell lung cancer patients account for 5-11% of non-small cell lung cancer patients. %about. [0003] ALK, also known as Ki-1, CD246, is a receptor-like tyrosine kinase that is highly expressed in the nervous system of the human embryo, while adult ALK is selective in brain nerve cells, epithelial cells and vascular endothelial cells limited expression. Fusion genes resulting from fusions of the ALK gene with other genes are mostly oncogenic; eg, NPM-ALK in anaplastic large cell lymphoma and EML4-ALK in NSCLC (non-small cell lung canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4545A61P35/00
Inventor 欧阳强张成景书谦
Owner GMAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com